Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882905 | 1.00 | AKR1C3 (0.42) | AKR1C3PTGS2FAAHPTGS1AKR1C2 | |
| SCHEMBL7887232 | 0.89 | PTGS2 (0.48) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL7802251 | 0.89 | PTGS2 (0.48) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL7802249 | 0.89 | PTGS2 (0.48) | PTGS2PTGS1ABCB11ALDH1A1MT-CO2 | |
| SCHEMBL7806110 | 0.89 | PTGS2 (0.46) | AKR1C3PTGS2PTGS1AKR1C2MAOB | |
| SCHEMBL7806112 | 0.89 | PTGS2 (0.46) | AKR1C3PTGS2PTGS1AKR1C2MAOB | |
| SCHEMBL7807200 | 0.88 | PTGS2 (0.47) | AKR1C3PTGS2PTGS1 | |
| SCHEMBL7807198 | 0.88 | PTGS2 (0.47) | AKR1C3PTGS2PTGS1 | |
| SCHEMBL7806930 | 0.86 | PTGS2 (0.46) | AKR1C3PTGS2PTGS1AKR1C2ADORA3 | |
| SCHEMBL7807292 | 0.86 | PTGS2 (0.48) | AKR1C3PTGS2PTGS1AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040185110-A1 | Formulations of low solubility bioactive agents and processes for making the same | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | claimed |
| WO-2004043358-A2 | FORMULATIONS OF LOW SOLUBILITY BIOACTIVE AGENTS AND PROCESSES FOR MAKING THE SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | claimed |
| EP-1207856-A2 | COFORMULATION METHODS AND THEIR PRODUCTS | Bradford Particle Design Limited (GB) | 2002-05-29 | — | — | EP | claimed |
| WO-2001015664-A2 | COFORMULATION METHODS AND THEIR PRODUCTS | BRADFORD PARTICLE DESIGN LIMITED (GB) | 2001-03-08 | — | — | WO | claimed |
| US-6180651-B1 | ANTIINFLAMMATORY AGENTS; ANALGESICS | BRISTOL-MYERS SQUIBB | 2001-01-30 | — | — | US | claimed |
| EP-1207856-A2 | COFORMULATION METHODS AND THEIR PRODUCTS | Bradford Particle Design Limited (GB) | 2002-05-29 | — | — | EP | disclosed |
| EP-0891345-B1 | NOVEL FURAN DIARYLMETHYLIDENE DERIVATIVES, METHOD FOR THEIR PREPARATION AND THERAPEUTICAL USES THEREOF | UNION PHARMA SCIENT APPL (FR) | 2001-08-16 | — | — | EP | disclosed |
| WO-2001015664-A2 | COFORMULATION METHODS AND THEIR PRODUCTS | BRADFORD PARTICLE DESIGN LIMITED (GB) | 2001-03-08 | — | — | WO | disclosed |
| US-6180651-B1 | ANTIINFLAMMATORY AGENTS; ANALGESICS | BRISTOL-MYERS SQUIBB | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040185110-A1 | Formulations of low solubility bioactive agents and processes for making the same | BMP1, BMP2, MMP7 | AKR1C3 2218/4885PTGS2 1383/4885FAAH 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.